These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28401745)

  • 41. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The analysis of leukemic relapse after allogeneic bone marrow transplantation].
    Yoshimura M; Yoshida H; Matsunashi T; Hidaka S; Kobayashi M; Yoshida S; Tominaga N; Tejima H; Hiraoka A; Nakamura H
    Rinsho Ketsueki; 1991 Nov; 32(11):1433-8. PubMed ID: 1758050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia.
    Greinix HT; Reiter E; Schulenburg A; Keil F; Lechner K; Fischer G; Rosenmayr A; Leitner G; Kalhs P
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S53-6. PubMed ID: 9916636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment results of bone marrow transplantation in Kyushu Cancer Center. Bone Marrow Transplantation Team].
    Tasaka H; Ikuno Y; Okamura J
    Rinsho Ketsueki; 1990 Mar; 31(3):315-9. PubMed ID: 2366334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Bone marrow transplantation in Mexico. Report of the 1st successful case in acute myeloblastic leukemia. Grupo de Trasplante Medular Oseo del INNSZ].
    León E; Sosa R
    Rev Invest Clin; 1992; 44(3):383-6. PubMed ID: 1488582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
    Nakai K; Tajima K; Kishimoto Y; Katsura K; Kawamura M; Yamamoto Y; Hanada M; Zen K; Amakawa R; Fujimoto M; Fukuhara S
    Rinsho Ketsueki; 2000 Jan; 41(1):25-31. PubMed ID: 10695395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Allogenic bone marrow transplantation in acute leukemia].
    Kier P; Hinterberger W
    Wien Med Wochenschr; 1991; 141(9-10):221-4. PubMed ID: 1949849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.
    Jourdan E; Maraninchi D; Reiffers J; Archimbaud E; Michallet M; Harousseau JL; Ifrah N; Rio B; Guyotat D; Guilhot F
    Leukemia; 1995 Jun; 9(6):1068-71. PubMed ID: 7596171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hypocellular acute leukemia].
    Tomonaga M
    Rinsho Ketsueki; 1995 May; 36(5):457-64. PubMed ID: 7783351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclosporine-induced encephalopathy in a patient with relapsed acute myeloid leukemia treated with unrelated allogeneic bone marrow transplantation.
    Chen YC; Chao TY; Chen CY; Ho CL
    J Formos Med Assoc; 2000 Mar; 99(3):248-51. PubMed ID: 10820959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
    Fagioli F; Bacigalupo A; Frassoni F; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Clavio M; Vitale V; Sogno G
    Bone Marrow Transplant; 1994 Mar; 13(3):247-52. PubMed ID: 8199567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
    Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hypoplastic acute promyelocytic leukemia with continuous hypocellular bone marrow after remission].
    Nakamura T; Makiyama J; Matsuura A; Kurohama H; Kitanosono H; Ito M; Yoshida S; Miyazaki Y
    Rinsho Ketsueki; 2018; 59(4):414-419. PubMed ID: 29743401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early occurrence of an adenocarcinoma after allogeneic bone marrow transplantation in a patient with AML.
    Germing U; Kobbe G; Sohngen D; Motherby H; Braunstein S; Heyll A; Aul C
    Oncol Rep; 1999; 6(4):855-7. PubMed ID: 10373670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.